Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox + Cytarabine in Acute Leukemia
NCT02413021Phase 1Unknown
- Start
- May 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of deferasirox in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (2 arms). Primary endpoint: Complete Remission at 1 month. Status: unknown.
02
Drugs
deferasirox
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02413021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02413021.